ISENTRESS inhibits the HIV-1 integrase enzyme, preventing the viral DNA from integrating into the human genome, thereby stopping virus replication.
Recommended for:
Adults with confirmed HIV-1 infection
As a first-line component of combination antiretroviral therapy
Patients with resistance to other classes of antiretroviral drugs
Adolescents aged 12 years and above (based on weight and medical guidance)
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART)
Take orally with or without food. The standard dosage is 400 mg twice daily, but treatment should be supervised and adjusted by a healthcare professional based on clinical status.
Contraindications:
Hypersensitivity to raltegravir or excipients
Children under 12 years (for this dosage form)
Side Effects:
Nausea, diarrhoea
Headache, insomnia
Elevated liver enzymes
Allergic reactions (rash, itching, angioedema)
Rare: Rhabdomyolysis, depression